COVID-19 health concern continues to decline in November: Poll
The health concern over COVID-19 declined for the third consecutive month in November, shows the...
News
Kazia reports positive results from Phase II trial of glioblastoma therapy
Treatment with paxalisib provided a median OS and PFS of 15.7 months and 8.4 months,...
J&J’s Covid-19 booster shot offers greater antibody responses
J&J’s booster given after Pfizer-BioNTech’s two-dose regimen led to a continued rise of antibodies for...
FDA approves InteRNA Technologies’ Phase I solid tumour treatment study
The Phase I/Ib trial will assess the pharmacodynamics, pharmacokinetics, preliminary efficacy, and safety of INT-1B3.
Acasti Pharma reports positive interim data from SAH therapy trial
The trial will compare and assess GTX-104’s relative bioavailability with the oral nimodipine capsules.
Hepagene begins Phase IIa clinical trial of HPG1860 to treat NASH
The Phase IIa clinical trial will assess the tolerability, efficacy, and safety of HPG1860.
ARCA biopharma completes enrolment in Phase IIb Covid-19 therapy trial
The trial will assess two dose levels of the small recombinant protein versus heparin in hospitalised Covid-19 patients.
Ultragenyx Pharmaceutical begins dosing in study of GSDIII therapy
The Phase I/II trial will assess the efficacy, safety, and tolerability of UX053 in GSDIII patients aged 18 and above.
QSAM begins patient enrolment for bone cancer therapy trial
The dose escalation study will determine CycloSam’s maximum tolerated dose in bone cancer patients.
Revelation Biosciences begins Phase IIb trial of H3N2 influenza therapy
The viral challenge study will enrol up to 60 healthy individuals aged 18 to 55 years.
Sobi and Selecta Biosciences complete enrolment for gout therapy trial
The DISSOLVE I study will assess the efficacy and safety of SEL-212 to treat chronic refractory gout.
